Edrecolomab, also known as M-BVAC, is a recombinant monoclonal antibody used for the treatment of colorectal cancer. It works by targeting a specific protein which is found on certain types of cancer cells. By binding to this protein, Edrecolomab helps to stop the growth and spread of cancer cells. It is usually used in combination with other chemotherapy drugs. Edrecolomab has been approved by the U.S. Food and Drug Administration (FDA) for the treatment of colorectal cancer that has spread to other parts of the body or cannot be removed by surgery.
Edrecolomab, also known by the trade name Panorex, is a medication that was investigated for its potential use in treating colorectal cancer. Here's a breakdown of what we know about Edrecolomab:
Type of Drug:
- Edrecolomab is a mouse-derived monoclonal antibody. [ monoclonal antibody - a lab-made protein that can target specific cells or substances]
Target:
- It targets a protein called EpCAM (epithelial cell adhesion molecule), which is found on the surface of various epithelial tissues and some cancer cells, particularly colorectal cancers.
Development:
- Initial studies showed promise for Edrecolomab in treating stage III colorectal cancer (cancer that has spread to the lymph nodes).
- However, further trials haven't shown conclusive benefits for stage II (localized cancer) or when used in combination with other therapies for advanced stages.
- Due to limited effectiveness, Edrecolomab is not currently widely used. Research is focused on exploring its use in other cancer types.
Side Effects:
- Edrecolomab was generally well-tolerated in studies.
- Common side effects reported include flushing, skin redness, diarrhea, abdominal pain, nausea, and vomiting.
- Because it's derived from mice, there's a risk of allergic reactions in some patients.
Current Status:
- Edrecolomab is not a standard treatment for colorectal cancer due to the availability of more effective options.
- Research on its use in other cancers is ongoing.